重要 #ESMO26 研究，发表于 @Annals_Oncology！
在 PD-L1 ≥50% 的晚期肺癌患者中，3 期 PERSEE 试验评估了在 pembrolizumab 基础上加用化疗，将中位无进展生存期从 6.9 个月延长至 16.1 个月（HR 0.56）。
中位总生存期为 50.2 vs 29.9 个月（HR 0.77），尽管该差异未达到统计学显著性。
≥3 级治疗相关不良事件增加（54% vs 19%）。
这是针对 PD-L1 高表达肺癌一线治疗决策的一项重要发现。
271 浏览 · 2 赞 · 2 转发 · 1 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSymbiotic-GYN-18 (GOG-3145/ENGOT-EN37/APGOT-EN6/LACOG 0426-EVA): Phase 3 study of PF-08634456 in combination with pembrolizumab versus placebo plus pembrolizumab in participants with advanced or recurrent endometrial cancer
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org- ilyas sahin, MD@ilyassahinMD
https://www.annalsofoncology.org/article/S0923-7534(26)06892-4/fulltext
来源：ilyas sahin, MD · x.com